MARY ZAYAS: Open Payments
NPI 1811137870 · NEW YORK, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$670 in 28 payments from 10 companies in 2025. Trend: 2023 $0 · 2024 $330 · 2025 $670
Food & beverage: $670
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 6 | $236 |
| AstraZeneca Pharmaceuticals LP | 9 | $162 |
| ABBVIE INC. | 4 | $82 |
| Lilly USA, LLC | 3 | $68 |
| Abbott Laboratories | 1 | $24 |
| Renalytix AI, Inc. | 1 | $22 |
| Amgen Inc. | 1 | $21 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $19 |
| Exact Sciences Corporation | 1 | $18 |
| SHIELD THERAPEUTICS INC | 1 | $18 |
Products named: AIRSUPRA, Wegovy, Ozempic, MOUNJARO, QULIPTA, Rybelsus, FREESTYLE LIBRE 2, ZEPBOUND.
Industry payments across NY — which companies pay providers there.
